Liubota R V, Zotov A S, Vereshchako R I, Liubota I I, Zaychuk V V
Department of Oncology, National Medical University, 13 Boulevard Shevchenko, Kiev 01030, Ukraine.
Kiev Oncology Municipal Centre, Kiev, Ukraine.
Biomed Res Int. 2015;2015:789646. doi: 10.1155/2015/789646. Epub 2015 Aug 3.
The aim of the research was to estimate the frequency of the locoregional breast cancer recurrence appearance, the recurrence-free period continuance, and the 3- and 5-year survival depending on the scope of the surgical intervention, menstrual profile, and histological and molecular-biologic characteristics of the primary tumor.
Among 218 patients with a breast cancer, 99 patients had breast-conserving surgery (BCS) and 119 underwent radical mastectomy (RME); all patients had regional lymphatic nodes dissection. The size and the primary tumor differentiation degree, metastasis presence in the regional lymph nodes, ER expression, PR, and Her/2neu were assessed as the prognostics factors.
It was defined that the locoregional recurrence appearance frequency in patients with BCS turned out to be 13%, and in patients after RME it turned out to be 9%; the recurrence-free period continuance was 53 ± 8 months and 56 ± 10 months, respectively.
The locoregional cancer recurrence frequency is higher in women with the menstrual function being preserved at the moment of the primary tumor detection than in postmenopausal patients and also in patients having the hyperexpression of the Her/2neu. The ipsilateral cancer recurrence decreases the 3-year survival by 7,1% and the 5-year one by 20,3%, respectively.
本研究旨在根据手术干预范围、月经情况以及原发肿瘤的组织学和分子生物学特征，评估局部区域乳腺癌复发的频率、无复发生存期的持续时间以及3年和5年生存率。
在218例乳腺癌患者中，99例行保乳手术（BCS），119例行根治性乳房切除术（RME）；所有患者均行区域淋巴结清扫术。评估肿瘤大小、原发肿瘤分化程度、区域淋巴结转移情况、雌激素受体（ER）表达、孕激素受体（PR）以及人表皮生长因子受体2（Her/2neu）作为预后因素。
结果显示，保乳手术患者的局部区域复发频率为13%，根治性乳房切除术后患者的局部区域复发频率为9%；无复发生存期分别为53±8个月和56±10个月。
在原发肿瘤检测时保留月经功能的女性中，局部区域癌症复发频率高于绝经后患者以及Her/2neu过表达的患者。同侧癌症复发分别使3年生存率降低7.1%，5年生存率降低20.3%。
